FDAsafety guidance66% confidence
BsUFA II: Assessment of the Program for Enhanced Review Transparency and Communication in the Biosimilar User Fee Act
Source: FDA
Why This Matters
Why this matters: provides agency context on safety guidance that may shape timing or evidence expectations for TEVA PHARMACEUTICALS, INC; the same agency is already in play for this signal, so precedent weight is higher.
Regulatory Analysis
Over the years, FDA has worked to increase communication between Agency staff and applicants during the review of novel drug and original biologic applications. The goal has been to enhance the transparency, predictability, effectiveness, and efficiency of the review process.
Supporting Context
- Therapeutic area
- Not specified
- Sub-indication
- General
Related signal: TEVA Pharmaceuticals submits ANDA219413 for FDA review